Patients with moderate or severe hepatic impairment should be treated with reduced starting doses and closely monitored.

Related Posts:

1. Velcade (bortezomib): Starting Dose Adjustments for Patients with Hepatic Impairment
2. Exjade (deferasirox): Boxed Warning
3. Vivitrol (naltrexone for extended-release injectable suspension): Medication Guide Required for Patients
4. Promacta (eltrombopag): Portal Venous System Thromboses in Study of Patients With Chronic Liver Disease
5. Sprycel (dasatinib): Drug Safety Communication – Risk of Pulmonary Arterial Hypertension